Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure
Patent No. EP3294283 (titled "Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure") was filed by Novartis on May 9, 2016. The application was issued on Mar 8, 2023.
Patent Summary
Treatment of heart failure in a human patient that prevents the onset of a disease characterized and / or manifested by atrial enlargement and/or remodeling. The treatment comprises administering to a patient in need thereof a twice-daily target dose of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug, wherein said target dose is reached after a titration with an initial lower twice-daily dose of said ARNI increasing to the twice daily target dose from 5 to 8 weeks.
Patent Family
Patent Oppositions (17)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
EP3294283
- Application Number
- EP16722388A
- Filing Date
- May 9, 2016
- Status
- Granted And Under Opposition
- Feb 3, 2023
- Publication Date
- Mar 8, 2023
- External Links
- Slate, Register , Google Patents